Holen Sie sich die Stockscreener-App
8.7926
1.76%
-0.1574
Handel nachbörslich:
8.66
-0.1326
-1.51%
Schlusskurs vom Vortag:
$8.95
Offen:
$8.61
24-Stunden-Volumen:
11,609
Relative Volume:
0.37
Marktkapitalisierung:
$34.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.77M
KGV:
-12.04
EPS:
-0.73
Netto-Cashflow:
$-17.36M
1W Leistung:
-17.44%
1M Leistung:
+11.87%
6M Leistung:
+7.24%
1J Leistung:
-7.45%
1-Tages-Spanne:
$8.385
$8.80
1-Wochen-Bereich:
$7.90
$10.74
52-Wochen-Spanne:
$4.5601
$19.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Firmenname
Mink Therapeutics Inc
Sektor
Branche
Telefon
212-994-8250
Adresse
149 FIFTH AVENUE, NEW YORK
Vergleichen Sie INKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
8.7926 | 34.08M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten
What is HC Wainwright’s Estimate for INKT Q1 Earnings? - Defense World
Brokers Set Expectations for INKT FY2029 Earnings - Defense World
MiNK Therapeutics stock target soars to $35 at H.C. Wainwright By Investing.com - Investing.com South Africa
MiNK Therapeutics stock target soars to $35 at H.C. Wainwright - Investing.com
MiNK Therapeutics presents allo-iNKTs combination data in 2L gastric cancer - TipRanks
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs - GlobeNewswire
MiNK Therapeutics Presents Promising Data from Phase 2 Study of Allo-iNKT Cell Therapy AgenT-797 at AACR Meeting - Nasdaq
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting - The Manila Times
Can This Novel Cancer Therapy Revolutionize Gastric Cancer Treatment? New Clinical Data Reveals Answer - StockTitan
How the (INKT) price action is used to our Advantage - Stock Traders Daily
MiNK Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Nigeria
MiNK Therapeutics Announces Regained Compliance With Nasdaq Listing Requirements - Nasdaq
MiNK Therapeutics regains Nasdaq compliance - Investing.com India
Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences - The Manila Times
MiNK Therapeutics Regains Compliance with Nasdaq Listing Requirements - Nasdaq
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements - GlobeNewswire
Can MiNK Therapeutics' Nasdaq Compliance Victory Signal a Turnaround for iNKT Cell Therapy Pioneer? - StockTitan
Stocks Surge Across Health Services and Industry Sectors: Nuvve, Exagen, and Flexsteel Lead the Way - HPBL
(INKT) Trading Advice - Stock Traders Daily
Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting - BioSpace
Finanzdaten der Mink Therapeutics Inc-Aktie (INKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):